
News|Articles|October 9, 2012
FDA approves cysteamine ophthalmic solution 0.44% for treatment of corneal cystine crystals in cystinosis patients
FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44%, a topical ophthalmic therapeutic, developed in partnership with the National Institutes of Health (NIH), for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
PBM reform. It has finally happened
3
Study of antibody-Keytruda combination seeds hope for overcoming immune checkpoint inhibitor resistance, use of biomarkers
4
Melanoma diagnoses projected to rise in 2026
5























